Q3 2026 Divi's Laboratories Ltd Earnings Call Transcript
Key Points
- Divi's Laboratories Ltd (BOM:532488) reported a consolidated total income of INR2,692 crores for Q3 FY 2026, up from INR2,401 crores in the same quarter last year, indicating improved operating performance.
- The company maintained a strong export performance, with exports constituting approximately 89% of total sales revenue, and Europe and the United States contributing 73% of export sales.
- The Nutraceutical segment delivered a healthy performance, contributing INR214 crores to the revenue, and marking 20 years of Divi's Nutraceuticals.
- Divi's Laboratories Ltd successfully concluded a US FDA general CGMP inspection at its Unit 1 Choutuppal facility, reaffirming its commitment to quality and regulatory compliance.
- The company has been actively engaged in several RFPs and customer visits in the Custom Synthesis segment, with multiple projects progressing well and moving closer to commercial volumes over the next year.
- The pricing environment in the Generics segment remains competitive, impacting value growth despite healthy volume traction.
- The company faced a one-time incremental impact of INR74 crores relating to employee benefit obligations due to changes in labor codes, which was disclosed as an exceptional item.
- Raw material prices and availability, while broadly stable, are subject to potential pressures due to external developments such as China's withdrawal of export tax rebates.
- The company is operating at 70% to 80% capacity utilization, indicating potential constraints in meeting future demand without further capacity expansion.
- There is uncertainty regarding the impact of geopolitical developments and evolving policy frameworks on the company's operations and input costs.
Ladies and gentlemen, good day, and welcome to the earnings conference call of Divi's Laboratories Limited for Q3 FY 2026. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Mr. M. Satish Choudhury. Thank you, and over to you, sir.
'- -
Thank you. Good afternoon to all of you. I'm M. Satish Choudhury, Company Secretary and Chief Investor Relations Officer of Divi's Laboratories Limited. I welcome you all to the earnings call of the company for the quarter and 9 months ended 31st December 2025.
From Divi's Labs, we have with us today Dr. Kiran S. Divi, Whole-Time Director and Chief Executive Officer, Ms. Nilima Prasad Divi, Whole-Time Director, Commercial and Mr. Venkatesa Perumallu Pasumarthy, Chief Financial Officer.
During the day, our Board has approved unaudited financial results for the quarter and 9 months ended 31st December 2025, and we have
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
